The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 286.00
Bid: 286.50
Ask: 291.00
Change: 22.50 (8.54%)
Spread: 4.50 (1.571%)
Open: 262.00
High: 295.00
Low: 262.00
Prev. Close: 263.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Perstorp Belgium

6 Mar 2017 07:02

RNS Number : 5461Y
Synthomer PLC
06 March 2017
 

The Company considers this announcement to contain inside information

 

6 March 2017

Synthomer plc

Acquisition of Perstorp Oxo Belgium AB

 

Synthomer plc (LSE:SYNT) ('Synthomer' or the 'Group'), a leading speciality chemicals company, today announces the acquisition of Perstorp Oxo Belgium AB ('Perstorp Belgium') from The Perstorp Group, a speciality chemicals innovator and supplier based in Sweden.

 

Synthomer will pay an enterprise value of €78 million which will be fully funded from existing financial resources. The acquisition, which completed on 5 March, represents a multiple of 8.5x 2016 Adjusted EBITDA(1). This is expected to fall to approximately 7.0x EBITDA post integration reflecting operational efficiencies and increased volumes to existing customers. Perstorp Belgium will be consolidated into Synthomer's results from March 2017.

 

In the year to 31 December 2016, Perstorp Belgium generated reported earnings before interest and tax of €8 million. At 31 December 2016, Perstorp Belgium had gross assets of €21 million.

 

Perstorp Belgium is a niche performance additives business serving the decorative and industrial coatings industries. It has strong market leadership positions (#1 or #2) and serves a highly attractive, blue-chip customer base. The business operates from a well located, single site in Ghent, Belgium where there is potential for growth capacity for future demand.

 

Perstorp Belgium is highly complementary to Synthomer's existing markets and customers. The Group will focus on expanding Perstorp Belgium's market position by developing closer relationships with customers through leveraging its existing sales and technical services infrastructure, and driving operational performance.

 

Calum MacLean, Chief Executive Officer of Synthomer, commented:

"The acquisition of Perstorp Belgium represents another step forward in our strategy to continue to grow and develop Synthomer. The business is an excellent fit and provides increased access to new products and customers. We look forward to welcoming our new colleagues and integrating the business with Synthomer through the remainder of this year."

 

Note 1 - Reported EBITDA of €8.8m excluding certain Perstorp Group overhead cost allocations of €0.3m resulting in Adjusted EBITDA of €9.1m

 

-Ends-

Enquiries:

Calum MacLean, Chief Executive Officer

Tel: 01279 436211

Stephen Bennett, Chief Financial Officer

Tel: 01279 436211

Charles Armitstead, Teneo Blue Rubicon

Tel: 020 3603 5220

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQLLFIDVRIEIID
Date   Source Headline
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding
30th Jul 201912:59 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:55 pmRNSDirector/PDMR Shareholding
30th Jul 201912:54 pmRNSDirector/PDMR Shareholding
30th Jul 201912:53 pmRNSDirector/PDMR Shareholding
30th Jul 201912:52 pmRNSDirector/PDMR Shareholding
30th Jul 201912:51 pmRNSDirector/PDMR Shareholding
30th Jul 201912:50 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201911:31 amRNSResults of Rump Placing
30th Jul 20197:00 amRNSResults of Rights Issue
26th Jul 20192:48 pmRNSDirector/PDMR Shareholding
26th Jul 20192:46 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.